Sygnature Discovery
Sygnature Discovery is a world-leading integrated drug discovery contract research organization, based in the UK and Canada, with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of close to 1,000 employees, including 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature has delivered 61 novel pre-clinical compounds, 38 of which have already progressed to clinical trials. Two have reached major milestones: one has been approved, and another is under regulatory review. Our scientists are named on more than 235 patents and our therapeutic areas of expertise span oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.
